Appeal No. 2001-1907 Page 2
Application No. 08/694,315
1. Activated immunoglobulin prepared by subjecting immunoglobulin to
an activating operation by admixing immunoglobulin with a histamine
component followed by removal of histamine from the mixture, wherein
the weight ratio of the histamine component admixed with the
immunoglobulin ranges from 0.015 to 150 mg of the histamine
component, to 1 gram of immunoglobulin, and wherein the amount of
histamine in the activated immunoglobulin after its removal from the
mixture is less than 0.2 nM.
15. A method of activating immunoglobulin comprising admixing
immunoglobulin with a histamine component to obtain a mixture and
then removing histamine from the mixture, wherein the weight ratio of
the histamine component admixed with the immunoglobulin ranges
from 0.015 to 150 mg of the histamine component, to 1 gram of
immunoglobulin, and wherein the amount of histamine in the activated
immunoglobulin after its removal from the mixture is less than 0.2 nM.
23. A method for treating demylenating disease, an autoimmune disease,
eosinophilia, inflammation, or allergic disease in a patient in need of
such treatment comprising administering a pharmaceutically effective
amount of activated immunoglobulin to said patient, wherein said
activated immunoglobulin is prepared by subjecting immunoglobulin to
an activating operation by admixing immunoglobulin with a histamine
component followed by removal of histamine from the mixture, wherein
the weight ratio of the histamine component admixed with the
immunoglobulin ranges from 0.015 to 150 mg of the histamine, to 1
gram of immunoglobulin, and wherein the amount of histamine in the
activated immunoglobulin after its removal from the mixture is less
than 0.2 nM.
The examiner relies upon the following references:
McMichael 4,705,685 Nov. 10, 1987
European Patent Application
Yoshii et al. (Yoshii I) 0 646 376 Apr. 05, 1995
Peacock, ”Structure, Synthesis, and Interaction of Fibrous Protein and Matrix,”
Wound Repair, 3rd Edition, pp. 96-97
Getlik et al. (Getlik),”Long-term investigation of the sensitivity threshold limit to
acetylcholine during the treatment of pneumoallergoses by histaglobin,” Pediat.
Dept. Postgrad. Inst., Trencin, Czech., Vol. 22, No. 3, pp. 211-217 Abstract No.
20482 (1967)
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 Next
Last modified: November 3, 2007